India, May 9 -- image credit- shutterstock

AstraZeneca India Pharma, a global, science-led, patient focused pharmaceutical company has announced a Central Drugs Standard Control Organisation (CDSCO) approvalto import for sale and distribution of Trastuzumab deruxtecan concentrate for solution for infusion 100 mg for an additional indication.

The medicine is now indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2- low (IHC 1+ and IHC 2+/ISH-) or HER2- ultralow (IHC0 with membrane staining) breast cancer, who have received at least one endocrine therapy in metastatic setting.

The global burden of breast cancer, identified by the World Health Organization (WHO) as the most diagnosed cancer, ...